文献速递肝病

靶向肝脏生物钟通过恢复TGF-β信号改善肝纤维化

Targeting the liver clock improves fibrosis by restoring TGF-β signaling.
PubMed 文献 · J Hepatol · 2024-08-22

本研究探讨昼夜节律钟(CC)对TGF-β信号及肝纤维化的调控作用。利用CC突变小鼠、健康及纤维化小鼠的肝星状细胞与肌成纤维细胞、人肝细胞与肌成纤维细胞功能缺失研究、单核转录组生物信息学分析及MASH相关纤维化小鼠模型和患者来源肝球体,发现CC振荡器在时间上门控TGF-β信号,此调控在纤维化中破坏;药理学调节CC-TGF-β信号可在体内小鼠模型及患者来源肝球体中抑制纤维化。

要点

  • CC振荡器在时间上门控TGF-β信号,该调控在纤维化中被破坏。
  • 肝星状细胞和肌成纤维细胞具有功能性CC,节律性表达包括促纤维化基因在内的众多基因。
  • 药理学调节CC-TGF-β信号可在小鼠模型和患者来源肝球体中抑制纤维化。

核心结论

  • CC调控TGF-β信号,该调控的破坏与患者肝纤维化相关;药理学概念验证研究揭示CC是肝纤维化的新治疗靶点,临床转化尚需进一步研究。

研究设计与样本

  • 使用CC突变小鼠、不同CC时相健康与纤维化小鼠富集的肝星状细胞和肌成纤维细胞、人肝细胞与肌成纤维细胞功能缺失研究、单核转录组生物信息学分析及细胞模型验证。
  • 采用MASH相关纤维化小鼠模型和患者来源肝球体进行药理学可靶向性与临床转化性的概念验证研究。

主要发现

  • CC振荡器在时间上门控TGF-β信号,此调控在纤维化中破坏。
  • 肝星状细胞和肌成纤维细胞具有功能性CC,节律性表达众多基因,包括促纤维化基因。
  • 肝细胞和肌成纤维细胞扰动研究显示TGF-β激活与CC扰动之间存在相互对应关系,并在患者来源离体和体内模型中得到确认。
  • 药理学调节CC-TGF-β信号在体内小鼠模型及患者来源肝球体中抑制纤维化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出临床转化尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liver fibrosis is the major driver of hepatocellular carcinoma and liver disease-related death. Approved antifibrotic therapies are absent and compounds in development have limited efficacy. Increased TGF-β signaling drives collagen deposition by hepatic stellate cells (HSCs)/myofibroblasts. Here, we aimed to dissect the role of the circadian clock (CC) in controlling TGF-β signaling and liver fibrosis. METHODS: Using CC-mutant mice, enriched HSCs and myofibroblasts obtained from healthy and fibrotic mice in different CC phases and loss-of-function studies in human hepatocytes and myofibroblasts, we investigated the relationship between CC and TGF-β signaling. We explored hepatocyte-myofibroblast communication through bioinformatic analyses of single-nuclei transcriptomes and performed validation in cell-based models. Using mouse models for MASH (metabolic dysfunction-associated steatohepatitis)-related fibrosis and spheroids from patients with liver disease, we performed proof-of-concept studies to validate pharmacological targetability and clinical translatability. RESULTS: We discovered that the CC oscillator temporally gates TGF-β signaling and this regulation is broken in fibrosis. We demonstrate that HSCs and myofibroblasts contain a functional CC with rhythmic expression of numerous genes, including fibrogenic genes. Perturbation studies in hepatocytes and myofibroblasts revealed a reciprocal relationship between TGF-β activation and CC perturbation, which was confirmed in patient-derived ex vivo and in vivo models. Pharmacological modulation of CC-TGF-β signaling inhibited fibrosis in mouse models in vivo as well as in patient-derived liver spheroids. CONCLUSION: The CC regulates TGF-β signaling, and the breakdown of this control is associated with liver fibrosis in patients. Pharmacological proof-of-concept studies across different models have uncovered the CC as a novel therapeutic target for liver fibrosis - a growing unmet medical need. IMPACT AND IMPLICATIONS: Liver fibrosis due to metabolic diseases is a global health challenge. Many liver functions are rhythmic throughout the day, being controlled by the circadian clock (CC). Here we demonstrate that regulation of the CC is perturbed upon chronic liver injury and this perturbation contributes to fibrotic disease. By showing that a compound targeting the CC improves liver fibrosis in patient-derived models, this study provides a novel therapeutic candidate strategy to treat fibrosis in patients. Additional studies will be needed for clinical translation. Since the findings uncover a previously undiscovered profibrotic mechanism and therapeutic target, the study is of interest for scientists investigating liver disease, clinical hepatologists and drug developers.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Crouchet E, Dachraoui M, Jühling F, et al. Targeting the liver clock improves fibrosis by restoring TGF-β signaling. J Hepatol. 2024. PMID: 39173955. doi:10.1016/j.jhep.2024.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。